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Abstract: Ghrelin is a hormone predominantly produced in and secreted from the stomach. Ghrelin is
involved in many physiological processes including feeding, the stress response, and in modulating
learning, memory and motivational processes. Ghrelin does this by binding to its receptor, the growth
hormone secretagogue receptor (GHSR), a receptor found in relatively high concentrations in
hypothalamic and mesolimbic brain regions. While the feeding and metabolic effects of ghrelin
can be explained by the effects of this hormone on regions of the brain that have a more permeable
blood brain barrier (BBB), ghrelin produced within the periphery demonstrates a limited ability to
reach extrahypothalamic regions where GHSRs are expressed. Therefore, one of the most pressing
unanswered questions plaguing ghrelin research is how GHSRs, distributed in brain regions protected
by the BBB, are activated despite ghrelin’s predominant peripheral production and poor ability to
transverse the BBB. This manuscript will describe how peripheral ghrelin activates central GHSRs to
encourage feeding, and how central ghrelin synthesis and ghrelin independent activation of GHSRs
may also contribute to the modulation of feeding behaviours.
Keywords: feeding; ghrelin; GHSR; blood brain barrier; vagal afferents; circumventricular organs;
central ghrelin synthesis; GHSR heterodimerization; GHSR constitutive activity
1. Introduction
1.1. Preface
Ghrelin is a 28 amino acid peptide hormone that influences many physiological processes
(adiposity, anxiety, feeding behaviours, memory, etc.) by binding and activating its endogenous seven
transmembrane G protein couple receptor (GPCR): The type 1a growth hormone secretagogue receptor
(GHSR) [1–10]. As one would expect given the multifaceted nature of ghrelin, GHSRs are widely
distributed within the brain (e.g., hypothalamus (HYP), ventral tegmental area (VTA), hippocampus
(HIP)) as well as in peripheral organs (e.g., adipose tissue, adrenals, stomach) [11–17]. However,
the ghrelin peptide, which is predominantly produced and secreted into the bloodstream by endocrine
gastric cells of the stomach, demonstrates a very limited ability to cross the blood brain barrier (BBB)
from the circulation into the brain (refer to Figure 1) [1,3,18–21]. Although some insist that ghrelin
is likewise produced in the brain, the validity of its central synthesis is a topic of contention [22–25].
Given its predominant peripheral production and poor ability to cross the BBB, one of the most
pressing unanswered questions plaguing ghrelin research is how GHSRs, which are widely distributed
in brain regions protected by the BBB, are activated to modulate ghrelin attributed processes and
behaviours. This apparent paradox has not been adequately addressed, an alarming fact considering
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the vast amount of resources that have been spent characterizing central GHSR dependent behaviours.
Moreover, the relevance and applicability of many ghrelin system studies heavily rely on reconciling
this knowledge gap. Accordingly, this paper discusses the most plausible means by which central
GHSRs are activated to modulate behaviour and highlights crucial studies that are needed to clarify
these mechanisms. As the ghrelin system’s ability to regulate feeding behaviours was recognized
shortly after ghrelin’s discovery and is perhaps the most renown; how the ghrelin system promotes
feeding behaviours despite the enigmatic spatial separation of GHSR and its endogenous ligand will
be the focus of this review.
Int. J. M l. Sci. 2017, 18, 859  2 of 44 
 
dependent behaviours. Moreover, the relevance and applicability of many ghrelin system studies 
heavily rely on reconciling this knowledge gap. Accordingly, this paper discusses the most plausible 
means by which central GHSRs are activated to modulate behaviour and highlights crucial studies 
that are needed to clarify these mechanisms. As the ghrelin system’s ability to regulate feeding 
behaviours was recognized shortly after ghrelin’s discovery and is perhaps the most renown; how 
the ghrelin system promotes feeding behaviours despite the enigmatic spatial separation of GHSR 
and its endogenous ligand will be the focus of this review. 
 
Figure 1. Illustration describing how peripherally produced ghrelin likely gains access to the brain. 
Ghrelin is primarily produced and secreted by the stomach although the small intestine and pancreas 
likewise produce a small quantity. Ghrelin O-acyltransferase (GOAT) converts des-acylated into its 
active acylated form capable of activating growth hormone secretagogue receptor (GHSRs) while 
esterases cleave acylated ghrelin’s O-octanoyl moiety returning it to its predominant inactive  
des-acylated ghrelin form (90% of total circulating ghrelin). Although des-acylated ghrelin is capable 
of crossing the blood brain barrier from the blood into the brain, acylated ghrelin demonstrates a very 
limited ability to do so (depicted by blue X). Accordingly, acylated ghrelin either stimulates GHSR on 
vagal afferents or bypasses the blood brain barrier (BBB) and activates GHSRs in or around 
circumventricular organs to convey its orexigenic effects. AP, area postrema; ARC, arcuate nucleus; 
ME, median eminence; NTS, nucleus tractus solitaries; SFO, subfornical organ. 
Figure 1. Illustration describing how peripherally produced ghrelin likely gains access to the
brain. Ghrelin is primarily produced and secreted by the stomach although the small intestine and
pancreas likewise produce a small quantity. Ghrelin O-acyltransferase (GOAT) converts des-acylated
into its active acylated form capable of activating growth hormone secretagogue receptor (GHSRs)
while esterases cleave acylated ghrelin’s O-octa oyl moiety returning it to its predominant inactive
des-acylated ghrelin f rm (90% of total circulating ghrelin). Although des-acylated gh elin is capable
of crossing the blo d brain barrier from the blo into the brain, acylated ghrelin demonstrates a
very limited ability to do so (depicted by blue X). Accordingly, acylated ghrelin either stimulates
GHSR on vagal afferents or bypasses the blood brain barrier (BBB) and activates GHSRs in or around
circumventricular organs to convey its orexigenic effects. AP, area postrema; ARC, arcuate nucleus;
ME, median eminence; NTS, nucleus tractus solitaries; SFO, subfornical organ.
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1.2. Ghrelin: The Feeding Peptide
Ghrelin is distinct from most peripherally produced feeding related signals as it is one of the
only ones that stimulates food intake [6,9,10]. Dubbed as “the feeding peptide”, its circulating
levels fluctuate with feeding status (high in the fasted state and low post-prandially) and
oscillate in time with scheduled meals [12,18,26–33]. Consistent with this, exogenous ghrelin
induces feeding when administered peripherally (i.e., intraperitoneal or intravenous) or centrally
(i.e., intracerebroventricular) [1,6,9,10,27,34]. Interestingly, ghrelin is even capable of eliciting feeding
during times of positive energy balance [6]. Conversely, GHSR antagonists block feeding traditionally
observed following ghrelin injections in ad libitum fed mice [1,6,35]. Likewise, GHSR antagonists
are capable of reducing food intake in food deprived rodents when endogenous levels of ghrelin are
high [36,37]. This in conjunction with the fact that ghrelin does not enhance feeding in GHSR null mice
strongly suggests that ghrelin enhances food intake via GHSR dependent processes [8,38].
The protein product of the ghrelin gene requires post translational modifications to generate
the active form of the ghrelin peptide (acyl-ghrelin) [39]. The pre-pro ghrelin peptide is cleaved
into two biologically active peptides, obestatin and des-acyl ghrelin, both of which appear to have
anorectic effects [39–43]. It has been suggested that obestatin may specifically inhibit ghrelin induced
food intake as many fail to see anorectic effects following administration of obestatin alone [44–48].
Des-acyl ghrelin is further modified (i.e., acylated) by ghrelin O-acyltransferase (GOAT) [6,8,20,49–51].
This modification, generally an octanoylation, occurs on serine-3 of the peptide and is required for the
orexigenic activity of ghrelin [50,51]. The addition of this side chain induces a conformational alteration
in the peptide that allows ghrelin to access the active binding site of the GHSR [49–51]. Interestingly,
the O-octanoyl moiety also makes acylated ghrelin much more hydrophobic [52]. This hydrophobicity
facilitates interactions between acylated ghrelin and the cellular membrane to encourage receptor
binding [52]. GOAT mRNA is ubiquitously expressed within many peripheral organs (e.g., adrenal
cortex, spleen, lungs, etc.) but is typically highest in organs that also strongly express ghrelin mRNA
(e.g., stomach and intestines) [50,53]. Like ghrelin, GOAT expression also fluctuates in response to
feeding status and diet [30,50,54–57]. Although initial studies demonstrated negligible expression of
GOAT in the brain, GOAT appears to be modestly expressed in the HYP, a brain region that is sensitive
to ghrelin and also credited with the putative ability to produce ghrelin [22,24,50,54,56].
Astonishingly, it is estimated that a mere 10% of circulating ghrelin is acylated and thus capable
of binding GHSRs to induce feeding [58]. While recent data suggest that the proportion of acyl ghrelin
may be higher, des-acyl ghrelin remains the principal form of ghrelin in blood [59]. Des-acyl ghrelin
does not seem to increase GHSR signalling at physiological concentrations [11,20,60,61] but see [62].
It has been proposed that supraphysiological concentrations of des-acylated ghrelin are needed to
bind GHSRs as des-acylated ghrelin lacks the O-octanoyl hydrophobic side chain that acylated ghrelin
uses to anchor itself in membranes [52,62]. Accordingly, des-acyl ghrelin is much less likely to
encounter and stay associated with cellular membranes and thus less likely to interact with GHSRs [52].
As mentioned above des-acyl ghrelin has been reported to influence feeding behaviours; however, the
data is inconsistent and is hypothesized to be mediated through a GHSR independent mechanism [63].
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1.3. Ghrelin’s Hypothalamic Modulation of Feeding
The HYP, which can be subdivided into many distinct nuclei such as the paraventricular
nucleus (PVN), lateral hypothalamic area (LHA), dorsomedial nucleus (DMH), ventromedial nucleus
(VMN), and the arcuate nucleus (ARC), is responsible for regulating homeostatic feeding and energy
balance [13,14,16,22,24,64–66]. All of these major hypothalamic nuclei express GHSRs and demonstrate
the capacity to initiate food intake in response to local ghrelin microinfusion [10,17,22,67–69]. The ARC,
which sits adjacent to the third ventricle and the median eminence (i.e., an important circumventricular
organ), is especially important as it has receptors for and is sensitive to most circulating hormones that
influence energy balance, including ghrelin [10,17,21,22,67–74] but see [75].
Accordingly, the ARC demonstrates increased c-Fos staining following central or peripheral
administration of ghrelin [76–78].Consistent with this, lesioning the ARC prevents the typical
increase in food intake that follows either central or peripheral ghrelin administration [79,80].
Not surprisingly, GHSR are expressed in the two major opposing cell types that regulate homeostatic
feeding, neuropeptide Y/agouti-related peptide/γ-aminobutyric acid (NPY/AGRP/GABA) and
to a lesser extentin proopiomelanocortin/cocaine and amphetamine regulated transcript neurons
(POMC/CART) [65]. Accordingly, ghrelin upregulates the expression of orexigenic peptide transcripts,
NPY and AGRP, but does not upregulate the anorectic peptide POMC within the ARC [81].
More importantly, although ghrelin binding studies show that ghrelin targets both of these cell
types, the direct effect of ghrelin on POMC/CART neurons has not be well characterized [21,22].
NPY/AGRP/GABA neurons enhance appetite when activated whereas POMC/CART neurons
promote satiety when stimulated [22,82–85]. Ghrelin enhances the activity of NPY/AGRP/GABA
neurons by both binding to GHSRs on their surface and by increasing the ratio of excitatory to
inhibitory afferents contacting them [22,86–88]. Moreover, the proportion of NPY/AGRP/GABA
neurons targeted by ghrein is higher when animals are fasted as one would expect when food procuring
behaviours are needed [21]. Conversely, ghrelin inhibits POMC/CART neurons by decreasing the
proportion of excitatory to inhibitory afferents innervating them and by directly increasing GABA
release from NPY/AGRP/GABA onto them [22,86–88]. Once activated NPY/AGRP/GABA neurons
stimulate feeding by increasing the production and release of NPY, AGRP, and GABA, which together
act to turn down satiety promoting pathways (Figure 2) [22,89–92]. As mentioned, GABA released
from NPY/AGRP/GABA neurons directly inhibits neighbouring POMC/CART neurons [22]. Second,
AGRP antagonizes the binding of POMC/CART neuron released α-melanocyte-stimulating hormone
(α-MSH) and β-MSH at melanocortin receptors (i.e., MC4) located in the PVN, LHA, and DMH,
to dampen anorectic outputs from these regions [82,89,90,93–96]. Lastly, the enhanced production
and release of NPY from NPY/AGRP/GABA projections innervating many other hypothalamic
nuclei (i.e., PVN, VMH, and LHA) likewise encourages appetite [64,89,91,96–98]. On the other hand,
shortly following meal consumption ghrelin levels drop whereas nutrient and hormonal satiety signals
rise [86]. Consequently, NPY/AGRP/GABA neuron activity drops off resulting in reduced inhibitory
(i.e., reduced GABA tone) control over POMC/CART neurons [22]. In addition, POMC/CART neuron
secreted anorectic peptides, α-MSH and β-MSH, are less antagonized by AGRP at melanocortin
receptors in the aforementioned regions of the HYP [64]. Likewise, NPY production and secretion
from NPY/AGRP/GABA neurons is attenuated [64]. Ultimately, the heightened production of α-MSH,
β-MSH, and CART from POMC neurons and reduced NPY/AGRP/GABAergic activity leads to
dampening of orexigenic pathways and the manifestation of satiety [64].
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1.4. Ghrelin’s Hedonic Regulation of Feeding
In addition to its role in promoting homeostatic feeding, within the HYP, ghrelin also influences
motivational and hedonic aspects of feeding behaviours [1,99–101]. Accordingly, administration of
ghrelin increases while disruption of the ghrelin system using antagonists or GHSR knockout (KO)
animals decreases the consumption of palatable foods [36,101–106]. Furthermore, ghrelin injections
facilitate the development of conditioned place preferences (CPP) and enhance bar press break points
for rewarding foods [37,107]. Conversely, GHSR antagonist treated and GHSR KO animals are unable
to develop CPP and demonstrate decreased break points for palatable foods [37,107].
The mesolimbic dopaminergic system has long been implicated in modulating behaviours that are
engaged whilst trying to acquire both natural (e.g., food) and drug rewards (e.g., cocaine) [1,108,109].
The activity of this system is driven primarily by a large population of dopamine neurons in the
mid brain (i.e., VTA), and their projections to the nucleus accumbens (NA), amygdala (AMY), HIP,
and prefrontal cortex (PFC) [108,109]. Lesion studies that attenuate dopamine release within this
pathway highlight its importance in controlling feeding behaviours [110,111]. Accordingly, lesioned
animals siginficantly decrease thier food intake and body weight [110,111]. Consistent with this,
the incentive properties of palatable foods induce increases in dopamine release within projectional
target regions such as the NA [112].
The VTA is one of the main brain regions where ghrelin acts to encourage hedonic and
motivational food related behaviours (Figure 2) [1,101,113]. In support of this, appreciable levels
of GHSR transcript are reported throughout the mesolimibic dompainergic system, especially within
the VTA [1,13,17]. VTA lesioned animals are less motivated to search and bar press for food following
central ghrelin infusions compared to controls [103,114,115]. Furthermore, intra-VTA infusions of
ghrelin stimulate feeding and enhance the motivation to work for palatable foods, whereas intra-VTA
ghrelin antagonists block ghrelin induced feeding and reduce motivation to obtain palatable food
rewards [1,101,113,116]. Interestingly, administration of a ghrelin antagonist into the VTA is not only
sufficent to reduce refeeding following a fast but also the motivation to obtain food rewards [1,101,113].
Ventricular infusions of ghrelin enhance phasic dopamine and NA neural activity in response to
food predictive cues [117]. Moreover, bath application of ghrelin to VTA brain slices enhances VTA
dopamine neuron activity [1] and intra-VTA microinfusions of ghrelin increases dopamine turnover in
the NA [1,118,119]. Interestingly, peripheral ghrelin administration is sufficient to increase dopamine
release within the nucleus accumbens following consumption of standard chow suggesting that
peripheral ghrelin is likewise capabale of directly or indirectly activating VTA dopamine neurons [120].
The ability of ghrelin to enhance dopamine release within the mesolimbic dopamine system has been
attributed to concomitant activation of GHSRs on VTA dopamine neurons and the enhancement of the
ratio of excitatory versus inhibitory afferents contacting them (Figure 2) [1]. Importantly, the excitation
of VTA dopamine neurons, enhanced dopamine turnover in the NA, and heightened feeding responses
that occur in response to ghrelin administation are not observed in GHSR KO mice [1]. Lastly, when
compared to GHSR KO animals, mice that solely express functional GHSRs on dopamine neurons,
have much better CPP scores when responding for palatable rewards and greater acute food intake in
response to ghrelin [121]. Collectively, these data exemplify the role that the ghrelin system plays in
regulating motivated feeding behaviours, highlight the VTA as an integral brain region whereby ghrelin
influences these behaviours, and demonstrate the importance of GHSRs in meditating these processes.
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Figure 2. Over simplified illustration depicting the two main brain regions where acylated ghrelin
(human ghrelin is black amino acid sequence and red letter substitution is rat) is proposed to target to
initate neurocircuits that promote feeding behaviours: the arcuate nucleus (ARC) of the hypothalamus
(HYP) and the ventral tegmental area (VTA). Within the ARC, ghrelin stimulates neuropeptide
Y/agouti-related peptide (NPY/AGRP) neurons by binding growth hormone secretagogue receptors
(GHSRs) on their surface. Once activated theses neurons produce and release γ-aminobutyric acid
(GABA) which inhibits anorectic proopiomelanocortin (POMC) neurons,decreasing the release of the
anorectic peptide α-melanocyte-stimulating hormone (α-MSH). This effectively reduces the quantity
of α-MSH capable of binding to satiety promoting melanocortin 4 receptors (Mc4Rs). Concurrently,
activated NPY/AGRP neurons increase their production and secretion of orexigenic peptides NPY
and AGRP. NPY binds to neuropeptide Y receptor type 1 (Y1R) and AGRP antagonizes the binding of
α-MSH at Mc4Rs. Together the reduction in anorectic peptide and enhancement of orexigenic ones
work to reduce the activity of second order anorexigenic neurons in the paraventricular nucleus (PVN)
to promote homeostatic feeding behaviours. Similarly, ghrelin also stimulates VTA dopamine (DA)
neurons increasing the frequency and probability of DA release from their projections in the nucleus
accumb ns (NA), prefrontal cortex (PFC), hippocampus (HIP), nd amygdala (AMY) to encourage
mesoli bic reward feeding. Ghrelin activates these VTA dopamine eurons both directly by binding to
GHSR rec ptors located on their surface and indirectly by increasing the ratio of excitatory to i hibitor
synapses contacting them.
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2. The Ghrelin and Growth Hormone Secretagogue Receptor Paradox
It is evident that ghrelin has the capacity to drive feeding related behaviours when injected directly
into the brain (i.e., most nuclei of the HYP, HIP, and VTA). Furthermore, neurons within these regions
express ghrelin receptors (transcript and protein) and are responsive to acyl ghrelin [1,4,11,13,14,17,22].
Paradoxically, ghrelin is widely accepted to be predominately produced in the periphery and to have
a very limited capacity to cross the BBB [19,21,122]. It is clear that there is a disjunction between
where central GHSRs are known to reside and ghrelin’s accessibility to these regions. The rest of this
manuscript will seek to explain the most plausible means by which the ghrelin system encourages
feeding through the activation of central GHSRs. As part of this, we discuss the putative role of
peripherally secreted ghrelin, centrally synthesized ghrelin, and ghrelin independent GHSR activity in
encouraging feeding behaviours.
2.1. Peripheral Ghrelin Activates Central Targets
Shortly after it was learned that the stomach supplies approximately 80% of total circulating
ghrelin but that centrally administered ghrelin also increases feeding, efforts were made to determine
if peripheral ghrelin was capable of activating central targets [6,18,20,28,123]. Accordingly, studies
looking at c-Fos expression (a reliable indicator of neuronal activation) following peripheral ghrelin
administration ensued (Figure 3) [124]. Early c-Fos experiments reported significant c-Fos expression
within the ARC, PVN, and DMH, but negligible expression within other GHSR positive feeding
related brain regions such as the hindbrain and remaining hypothalamic nuclei [13,17,78,123,125–127].
More recent studies, in addition to replicating data collected from early c-Fos studies, demonstrate
considerable c-Fos expression in sensory circumventricular regions such as the subfornical organ (SFO)
and area postrema (AP) as well as other brain regions that express GHSRs (i.e., amygdala, lateral
parabrachial nucleus, nucleus tractus solitarius (NTS), and the dorsal motor nucleus of the vagus nerve
(DMNV)) [13,17,122,128–130] but see [131]. The aforementioned c-Fos studies suggest that peripheral
ghrelin can activate many BBB protected brain regions in addition to more accessible brain regions
(i.e., ARC, AP, and SFO); however, they fail to describe whether ghrelin directly targets these BBB
privileged regions. It is important to note that c-Fos expression can be upregulated in downstream
activated cells of circuits influenced but not directly targeted by ghrelin. c-Fos experiments where
ghrelin is peripherally injected into GHSR KO mice that have GHSRs selectively rescued in specific
BBB-protected brain regions of interest should allow for the parsing out of direct versus indirect effects
of peripheral ghrelin within these regions. Nonetheless, the fact that peripheral ghrelin is unable
to stimulate feeding in transgenic mice that lack GHSRs in neurons substantiates the notion that
peripheral ghrelin targets central GHSRs to induce feeding [132].
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fluorescein-ghrelin signals follo ing peripheral and central ghrelin ad inistration. Fluorescein
ghrelin is a probe that has been used to deter ine hat brain regions nor al acylated ghrelin
accesses. It is a fluorescently tagged (fluorescein isothiocyanate) truncated analog of the ghrelin peptide
(i.e., 18 amino acids) with equivalent receptor stability, agonist activity, and binding affinity as acylated
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2.2. The Blood Brain Barrier
Although blood-cerebral spinal fluid, blood-labyrinth, blood-retina, blood-nerve and blood-brain
barriers work together to regulate the transport of molecules into and out of the central nervous
system, the latter is by far the largest and most commonly discussed blood-central nervous system
interface [134]. Unlike the fenestrated capillaries ubiquitously found in the periphery, a vast majority
of central nervous system capillaries are protected by the BBB. The BBB, which lines brain microvessels,
is composed of endothelial cells connected by tight junctions [135,136]. The BBB works in close
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concert with neighbouring cells, mainly pericytes, smooth muscle cells, and astrocytes, to maintain
a homeostatic neuroparenchymal microenvironment within the central nervous system [134,137].
In general, steroidal hormones (e.g., testosterone, estrogen) are able to cross the BBB by passive
transmembrane diffusion due to their small size and lipophilic nature; whereas, larger peptide
hormones (e.g., insulin, ghrelin) often require saturable specialized transporters to cross the BBB [138].
Accordingly, hormones that can enter the brain using non-saturable processes have similar blood and
brain concentrations [139]. In contrast, the rate in which peptide hormones are transported by saturable
mechanisms depends on the location and quantity of its corresponding transporter as well as its affinity
for its respective ligand, frequently resulting in different brain and blood concentrations [138,140].
2.3. Permeability of the Blood Brain Barrier to Ghrelin
The capacity of ghrelin to transverse the BBB was comprehensively described in a seminal
paper by Banks and colleagues [19], in which they tested the efficiency of three radioactively
labelled ghrelin peptides (i.e., human, mouse, and mouse des-acyl ghrelin) to cross the mouse
BBB in both the brain-to-blood and blood-to-brain direction. Reportedly, mouse acylated ghrelin
is transported in a saturable fashion only in the brain to blood direction but not in the blood to brain
direction; whereas, des-acyl ghrelin travels into the brain from the blood easily via nonsaturable
diffusion yet does not travel from the brain into the blood easily [19]. Interestingly, human ghrelin,
which differs in only 2 amino acids from that of mouse ghrelin, can cross the mouse BBB in both
directions via saturable transport [19]. Consistent with this, human ghrelin also demonstrates both
saturable binding and endocytosis in in vitro studies using rat cerebral microvessel endothelial cells
(i.e., RBE4 cells) [141]. Interestingly, lipid bilayer studies demonstrate that acylated ghrelin is incapable
of crossing lipid bilayers unaided suggesting that if peripheral ghrelin does access central brain regions
it is either via circumventricular organs or through a currently unidentified specialized saturable
transporter [52]. Modest and saturable radioactive signals can be detected in several regions of the
mouse brain (i.e., olfactory bulbs, occipital cortex, HYP, and HIP) following peripheral administration
of radioactively labelled human ghrelin [3,142]. Although using tagged human ghrelin to study the
capacity of ghrelin to cross the BBB and its central targets in mice is valuable, the data should be
interpreted with caution given that rodent ghrelin seems to have a very limited capacity to do so [19].
Moreover, although some have investigated ghrelin’s BBB permeability at physiologically relevant
times when the BBB is considered less impenetrable and ghrelin levels are naturally high (i.e., fasted or
food restricted animals) [21,142] most studies have not taken into account the nutritional status of their
experimental rodents [3,19,122]. Accordingly, recent data, utilizing fluorescently labelled truncated
forms of ghrelin, validated to have similar characteristics as normal acylated ghrelin (e.g., stability,
receptor binding, agonist activity), suggest that peripheral ghrelin is only capable of accessing the
ventromedial portion of the mouse HYP (i.e., ARC and median eminence) and that its capacity to do
so may rely on the energy state of tested rodents (a more detail discussion of these studies is found
elsewhere in this manuscript) [21,122,133].
One cannot ignore the possibility that mouse des-acyl ghrelin, which is more stable and capable
of crossing the BBB from the blood into the brain of mice, is produced peripherally but activated
centrally, especially given that the transcript for GOAT is found within the brain (i.e., HYP) and its
central knockdown has overt behavioural effects [54,56]. In support of this, although early studies
suggested endoplasmic reticulum residency of GOAT, GOAT protein has also been discovered in the
circulation of rodents [51,143]. The fact that the enzyme GOAT is not exclusively found intracellularly
hints at a putative extracellular mechanism of ghrelin acylation. Moreover, food restriction and
fasting both cause a consequential increase in hypothalamic GOAT mRNA expression suggesting
that this enzyme is upregulated and well situated to activate ghrelin during times of energy
insufficiency (i.e., when endogenous ghrelin levels are high) [18,26,27,30,56]. To our knowledge no one
has extensively characterized GOAT protein within the brain likely due to distrust of currently available
polyclonal antibodies targeting GOAT. Discovery and isolation of a reliable GOAT antibody and
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subsequent analysis of GOAT protein expression within feeding nuclei and/or within the cerebrospinal
fluid (CSF) needs to be completed before the notion of central activation of peripherally produced
ghrelin is revisited.
It is unknown whether endogenous acylated ghrelin is capable of crossing the BBB in humans
largely due to the invasiveness and limits of current techniques (e.g., brain microdialysis, CSF sampling)
capable of probing this question. Likewise, although post-mortem analysis of animal tissue has
provided some valuable information pertaining to the permeability of the brain to peripheral
ghrelin, these studies are impractical and unethical to conduct in humans [3,19,21,122]. As a result,
brain imaging studies (fMRI) have been widely adopted to investigate the effect of peripheral ghrelin
on the human brain [144–146]. Although these studies demonstrate that peripheral ghrelin selectively
activates particular feeding related brain regions, it remains unknown whether peripheral ghrelin
directly or indirectly targets these regions [144–146]. Positron emission tomography (PET), an imaging
technique that uses the decay of radioactive tracers attached to small biologically active molecules to
explore the functionality of organs, may be useful in determining whether peripheral ghrelin directly
targets central GHSRs. Fortunately, biologically active radioactive GHSR agonist tracers exist and may
prove useful in this regard [147]. Accordingly, GHSR competition assays that compare PET signals
following administration of these radioactively labelled GHSR agonists on their own to those obtained
proceeding co-administration of them with human ghrelin, should help clarify whether and the extent
to which peripheral ghrelin directly targets central GHSRs.
3. Peripheral Ghrelin Stimulates Appetite
3.1. Vagal Afferent Activation by Ghrelin
The vagus nerve (i.e., tenth cranial nerve) is integral for brain-gut communication. It mediates
the transmission of neural signals from the brain to the gastrointestinal system and likewise
conducts hormonal information from the gastroenteric system to the brain (Figure 1) [148–150].
Although the vagus nerve is comprised of both afferent and efferent nerve fibers; the vast majority
(i.e., approximately 90%) of neurons are afferent connections to the NTS [151]. Accordingly, the NTS
is the main brain region where feeding related afferent signals from the gastroenteric system are
integrated with descending hypothalamic information prior to the transfer of the amalgamated signal
to the HYP [149,150,152,153]. The ability of ghrelin to convey messages to the brain via the vagus
nerve was investigated shortly after its discovery in an attempt to uncover how ghrelin elicits its
central effects despite its predominant gastroenteric system production and poor transport across the
BBB [6,18–20,28].
Subdiaphragmatic vagotomy, gastric branch vagotomy, and selective destruction of vagal
nerve afferents completely eliminate the orexigenic effects that ensue following peripheral ghrelin
administration [123,154]. Furthermore, destruction of vagal afferents abolishes the upregulation of NPY
transcript and c-Fos expression that traditionally follow peripheral ghrelin administration [123,154].
It is important to note that vagotomised rodents maintain their ability to respond to centrally injected
ghrelin [123,154]. Similarly, vagotomised human patients also do not increase their food intake in
response to peripheral ghrelin injections [155]. Consistent with this, GHSR transcript is present in
vagal afferent cell bodies of the nodose ganglion and GHSR protein is found on axon terminals
innervating the gastrointestinal tract [123,156]. Electrophysiological studies demonstrate that in
contrast to anorectic peptides, ghrelin suppresses gastric vagal afferent activity at doses known to
enhance feeding [123,157].
Closer examination of the vagal afferent associated neural pathways that are engaged following
peripheral ghrelin administration led to the realization that projections from the NTS to the ARC of the
hypothalamus were required for the observed increases in food intake [152]. Specifically, Date and
colleagues [152] found that bilateral midbrain transections, which do not significantly alter feeding or
body weight on their own, severs the efferent fibers of the NTS to the ARC and completely abolishes
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the ability of peripheral ghrelin to induce feeding relative to controls. Again, these transections do
not prevent animals from increasing their food intake following central ghrelin administration [152].
The noradrenergic system appears to be intimately involved in mediating the central orexigenic effects
initiated by peripheral ghrelin [152]. More specifically, the noradrenergic system influences feeding
circuits downstream of the integration of vagal afferent signals within the NTS [152]. This notion is
supported by several pieces of evidence. First, the afferents sent to the HYP from the NTS are primarily
noradrenergic in nature [152,158]. Second, the enzyme that synthesizes noradrenaline (i.e., dopamine
β hydroxylase) is significantly increased in the NTS following peripheral ghrelin administration [152].
Third, bilateral midbrain transections prevent the increase in noradrenaline overflow within the ARC
seen following peripheral ghrelin injections [152]. Lastly, eliminating neurons in the hindbrain that
express dopamine β hydroxylase is sufficient to block the orexigenic effect of peripheral ghrelin [152].
While these data do not fully demonstrate that noradrenaline exclusively mediates the orexigenic
effects of ghrelin as adrenergic cells in the NTS also produce NPY (a potent orexigenic peptide),
these data support the idea that peripheral ghrelin exerts some of its orexigenic action through vagal
afferents that include the AP and the NTS.
Conversely, there are also reports that suggest that vagal afferents are not required for peripheral
ghrelin to stimulate feeding behaviours [159]. Studies conducted by Arnold and colleagues [159],
which used a very selective subdiaphragmatic vagal deafferentation method and stringent vetting
criteria of rodents that did not meet satisfactory deafferentation, show that intact vagal afferents are not
required to increase feeding after intravenous ghrelin. Even after adopting the same vagotomy method
as previous studies [154], Arnold and colleagues [159] report that vagotomised animals increase
their food intake to the same extent as sham lesioned animals following peripheral ghrelin treatment.
This indicates that vagal afferents are not absolutely essential to engage neural orexigenic pathways
following peripheral ghrelin administration and suggests that peripheral ghrelin also targets central
GHSRs to initiate feeding.
Together these studies demonstrate that peripheral ghrelin likely activates GHSRs within the
periphery (i.e., vagal afferents) as well as those found within the brain to induce feeding. It is
important to remember that both vagotomy and transection studies undoubtedly affect a plethora of
peripheral and central signals that influence feeding behaviours aside from those involved in ghrelin
signalling [160–162]. Therefore, caution must be taken in interpreting data from these studies and
efforts must be made to control for as many confounds as possible in future studies. Transgenic
model experiments that specifically allow one to manipulate GHSR positive cells of the vagal
afferent following peripheral ghrelin infusion will be valuable in elucidating the role that GHSR
positive vagal afferents have in transducing the orexigenic effect of peripheral ghrelin. For example,
Designer Receptors Exclusively Activated by Designer Drugs (DREADD)-based experiments could be
designed to evaluate feeding behaviours following peripheral administration of ghrelin whilst GHSR
positive vagal afferents are inhibited or excited. Alternatively, one could assess peripheral ghrelin
induced feeding behaviours in mice that have impaired GHSR function (i.e., knockout or knockdown)
specifically in vagal afferents to clarify the importance that GHSR positive vagal afferents have in
conveying peripheral ghrelin’s appetite stimulating effects.
3.2. Ghrelin and Circumventricular Organs
Circumventricular organs (CVOs) are unique brain regions that do not possess conventional
BBBs. As such they are important brain regions involved in the bi-directional transport of molecules
between the brain and the circulation. They are endowed with receptors for a variety of molecules
and have distinct capillary networks (i.e., fenestrated and curvy) that promote high blood volume but
low blood flow, features that facilitate the transfer of molecules into and out of the brain [75,163–165].
These specialized characteristics make CVOs abnormally sensitive to circulating substances that are
unable to cross the BBB due to their size, charge, chemical profile (i.e., lipophilic), or lack of specialized
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transport [139,165–168]. For these reasons CVO are of great interest to those probing the orexigenic
capacity and direct central targets of peripheral ghrelin.
Although CVOs more freely allow substances from the blood into the brain, they do so in a highly
regulated manner. Recently, specialized ependymal glial-like cells (i.e., tanycytes) that line portions
of the ventricles adjacent to CVOs, have been recognized as important for regulating the passage of
molecules between the blood, CSF, and the brain [169–172]. There are as many as eight proposed CVOs
(i.e., not all recognized as true CVOs) which belong to one of two main CVO categories: secretory or
sensory [167,173,174]. The well recognized and accepted secretory CVOs include the median eminence
(ME), neurohypophysis, pineal gland, and the intermediate lobe of the pituitary gland [173,174].
Conversely, the conventional sensory CVOs are the SFO, AP, and the vascular organ of the lamina
terminalis [173,174]. The focus here within will solely be on the median eminence, SFO, and the AP as
the peripheral action of ghrelin within these regions has been the most thoroughly investigated.
3.2.1. Median Eminence
The ME is situated below the third ventricle at the base of the HYP [175]. It shares its dorsal
lateral borders with the ARC [175]. Consistent with its classification as a CVO the ME houses a plexus
of fenestrated capillaries and is important for relaying messages between the brain and the rest of
the body [175–178]. The ME, considered a secretory CVO, is uniquely designed to allow hormones
produced in the brain to be dumped into the circulation but also, to some extent, permit circulating
substances to enter the ME [172]. Tanycyte cell bodies residing along the ventral surface of the
third ventricle (i.e., β-tanycytes) have cellular processes that make contact with blood vessels as they
make their way through the ventral-dorsal axis of the ME [169,177–179]. Originally, tanycytes were
thought to liberally move macromolecules bi-directionally between the blood and CSF via transcytotic
processes; however, this has been questioned by some [177,180,181]. Accordingly, when administered
intravenously, Evans Blue dye (common dye used to examine BBB integrity) is able to pass from
the blood into the ME via tanycyte processes but is not transported into the neighbouring ARC or
CSF [177]. Conversely, when Evans blue dye is administered into the third ventricle, lateral tanycytes,
which border the lateral sides of the third ventricle (i.e., α-tanycytes), transfer the dye into the ARC but
not into the ME or any other hypothalamic nucleus [177,181]. These data suggest that the bidirectional
transport of molecules from the blood into the ME and neighbouring hypothalamic regions as well
as the transfer from the CSF into these nuclei is a complex process regulated by different subtypes of
specialized cells (i.e., α and β tanycytes) [172].
The ME has long been a CVO of interest to ghrelin researchers due to its proximity to the ARC,
an indispensable brain region for the orexigenic effects elicited by ghrelin [79,80]. As aforementioned,
the ARC expresses GHSR mRNA and protein [13,14,17,65,79,80] and exhibits strong c-Fos staining in
response to peripheral ghrelin injections [78,125,127,130]. The neurocircuits that transduce ghrelin’s
orexigenic signal within this nucleus are also well characterized (Figure 1) [21,22,64,82–85,89–95,126].
Despite this, whether ghrelin directly targets the arcuate nucleus has, until recently, been unclear
due to disparate data concerning the permeability of the ARC’s BBB [71,126,167,182–185]. Moreover,
although speculated that ghrelin may bypass the BBB by travelling through the ME to the ARC,
this idea was deemed improbable due to the general limited diffusion of molecules within the brain
and aforementioned gating of transport between the ME and ARC by tanycytes [75,172,177,186–189].
Fortunately, McGirr and colleagues [133] designed a tool to test the capacity of ghrelin to access
central targets, a truncated 18 amino acid form of ghrelin (i.e., fluorescine-ghrelin) conjugated to a
fluorescent molecule (i.e., fluorescein isothiocyanate). Fluorescein-ghrelin is capable of stimulating
feeding and demonstrates equivalent receptor binding affinity, serum stability, and agonist activity
as endogenous acylatedghrelin [133,190]. Interestingly, a positive fluorescent signal is observed only
in the ARC and ME following peripheral administration of fluorescein-ghrelin at a dose that mimics
those found after an overnight fast in rodents (i.e., 2 fold increase in plasma ghrelin) or just prior to
meal initiation in humans [122]. Using a different fluorescently tagged bio-active ghrelin derivative
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(i.e., Cisbio Bioassays) and multiphoton microscopy techniques, Schaeffer and colleagues [21] found
that fluorescently labelled ghrelin travels from the circulation through fenestrated capillaries of the
ME into the ARC where it binds to NPY and POMC neurons. In these studies, no other GHSR rich
brain regions demonstrate detectable fluorescence [21]. Interestingly, fluorescence differed based on
nutritional status, with more positively labelled cells (i.e., higher total and NPY positive neurons but no
difference in number of positively labelled POMC neurons) in fasted relative to ad libitum fed mice [21].
These data supports the notion that physiologically relevant doses of peripheral ghrelin directly and
exclusively target the ARC. Moreover, these studies highlight the ME as an important region whereby
peripheral ghrelin enters the brain. However, because these studies utilized fluorescently labelled
truncated analogs of human ghrelin instead of full length tagged ghrelin from the indigenous species
in which it was to be tested in, it remains circumstantial evidence. Future experiments, which inject
full length fluorescently labelled ghrelin from the host species, are required to make more direct and
sound arguments concerning the central targets of peripherally produced ghrelin. Furthermore, an in
depth analysis of the capacity of ghrelin to access central targets during different nutritional states
(i.e., satiated versus fed) would be valuable given that the ability of ghrelin to enter the HYP appears
to be influenced by nutritional status [21].
3.2.2. Subfornical Organ
The SFO is located at the base of the fornix dorsal to the lamina terminalis and posteriorly
extends into the third ventricle [75,173,191]. Neurons within the SFO directly project to various
nuclei of the HYP (i.e., ARC, PVN, LH, supraoptic nucleus, lateral preoptic area) in addition to
the infralimbic cortex, bed nucleus of the stria terminalis, zona inceta, and brain stem [191–197].
Importantly, the SFO expresses receptors for and has the capacity to respond to many circulating
substances involved in energy balance, including ghrelin [130,195,198–200]. c-Fos data following
peripheral ghrelin administration is inconsistent within the SFO. Clear increases have been reported
by some while others fail to detect differences in ghrelin versus vehicle treated rats [130] but see [128].
Physiologically relevant doses of ghrelin stimulate specific subsets of neurons within the SFO that are
distinct from neurons which are activated by the anorectic peptide amylin [200]. This activation is
concentration dependent and blocked by GHSR antagonists suggesting that ghrelin levels must surpass
a certain threshold before GHSR activation is sufficient to stimulate SFO neurons [200]. These studies
are valuable in that they identify ghrelin responsive cells within the SFO; however, they do not address
whether endogenous ghrelin definitively targets the SFO to activate pathways involved in feeding
and/or to gain access to the CNS. A recent study that peripherally injected a fluorescent labelled
ghrelin analog suggests that the SFO is not one of the brain regions that peripheral ghrelin directly
targets to elicit its effects [122].
3.2.3. Area Postrema
The AP is situated at the intersection of the medulla and the spinal cord at the ventroposterior
boundary of the fourth ventricle [173]. The AP sends projections to a number of brain regions including
the NTS, reticular formation, lateral parabrachial nucleus, dorsal motor nucleus of the vagus, as well as
to tegmental nuclei within the brainstem [201–203]. Furthermore, it receives reciprocal inputs from the
NTS and lateral parabrachial nucleus in addition to those from the HYP (i.e., PVN and DMH) [201–203].
Consistent with its classification as a CVO, the AP is highly vascularised (i.e., by vessels not protected
by the BBB), contains neurons that express a wide variety of receptors, and is well situated to receive
circulating metabolic signals [173,198].
Perhaps not surprising given the ability of ghrelin to modulate energy balance processes, GHSR
transcript is highly expressed within the AP and neighbouring brain regions innervated by the
AP (i.e., NTS, and the DMNV) [17]. Consistent with this, GHSR-green fluorescent protein reporter
mice also demonstrate high expression of the GHSR protein within the dorsal vagal complex (DVC)
(i.e., AP, NTS, DMNV), particularly within the AP [14]. Correspondingly, injection of ghrelin into
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either the fourth ventricle or into the DVC induces a hyperphagic response [204]. Electrophysiological
experiments confirm that the AP houses neurons (~40%) that are responsive to physiological
concentrations of ghrelin [205]. Similar to neurons within the SFO, the response of neurons within the
AP is concentration dependent and blocked by application of a GHSR antagonist [205]. Peripheral
administration of ghrelin or ghrelin analogs induce strong c-Fos immunoreactivity in all brain
regions of the DVC [128–130,206]. Likewise, the AP is the only brain region, aside from the ARC,
that demonstrates a positive signal following peripheral administration of a fluorescently tagged
bioactive ghrelin analog (although at very high dose) [122]. Together these data suggest that peripheral
ghrelin may target the AP and associated feeding related brain regions that it innervates (e.g., NTS
and DMNV) to modulate food intake [122]. In support of this, lesion of the AP completely prevents
increases in c-Fos expression within the other two DVC brain regions (i.e., NTS and DMNV) following
peripheral ghrelin administration [129]. Further supporting that the AP is an important relay station
for the orexigenic effects elicited by peripheral ghrelin, AP lesioned animals do not increase their
food intake following chronic peripheral injections of ghrelin relative to controls [207]. It has been
suggested that projections from the DVC to the HYP are responsible for the orexigenic effects elicited
by ghrelin in the brainstem [149]; however, some argue that forebrain and hindbrain feeding circuits
are independent [152,208]. Either way, the AP is an important nucleus whereby peripheral ghrelin
conveys orexigenic signals.
4. The Role of Central Ghrelin in Stimulating Feeding
4.1. Central c-Fos Studies
Irrespective of current evidence suggesting minor passage of ghrelin from the periphery into the
CNS, it is indisputable that the central ghrelin system nonetheless plays an important role in regulating
feeding behaviours. Consistent with this, GHSRs are widely expressed within many distinct feeding
related brain regions such as the HYP, HIP, amygdala, VTA and the caudal brainstem [11,13,14,17,100].
Furthermore, biotin-labeled ghrelin experiments demonstrate that ghrelin efficiently binds GHSRs
in GHSR rich brain regions [1,3,22]. Accordingly, both microinfusion of ghrelin into GHSR rich brain
regions and intracerebroventricular (ICV) administration of ghrelin encourages motivated behaviours
to acquire and consume food [1,6,9,10,67,119,122,209]. Not surprisingly, c-Fos expression patterns
following ICV ghrelin administration closely resemble the distribution pattern of GHSRs, with dense
expression in brain regions known to influence feeding (Figure 3) [6,14,17,76,209]. Lastly, it has been
recently demonstrated that mice, which lack functional GHSRs specifically in neurons, do not increase
the amount they consume following peripheral ghrelin administration [132]. Given the aforementioned
evidence, it is clear that activation of central GHSRs encourages feeding behaviours.
4.2. Cerebrospinal Fluid Ghrelin
The clear induction of GHSR dependent behavioural effects (e.g., increased motivation to obtain
and consume foods) following ICV administration of ghrelin prompted questions concerning the origin
and physiological role of CSF ghrelin [1,10,119]. Although central CSF ghrelin levels have not been
quantified in rodents due to technical difficulties (i.e., large amount of sample is needed for current
assays), experiments conducted with human or sheep subjects report approximately 10 to 1000 fold
lower levels of ghrelin in the CSF relative to those found in blood [210,211]. In sheep, peripheral
injections of ghrelin that quickly raise circulating levels 10 fold only cause a doubling of CSF acylated
ghrelin levels (levels peaked 50 min after ghrelin injection) suggesting that although peripherally
injected ghrelin appears to be able to cross the BBB into the CSF its transport is limited and slow [210].
Moreover, it is not inconceivable that CSF ghrelin may also originate from central sources; however,
this notion remains controversial and will be discussed elsewhere in this manuscript [22–25]. Given
the few studies that have investigated CSF acylated ghrelin levels in conjunction with those that
have examined the concentration of acylated ghrelin required to induce reliable activation of GHSRs,
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it appears that CSF acylated ghrelin concentrations are likely inadequate to initiate GHSR dependent
processes [49,75,205,212,213]. Nonetheless, since diurnal CSF ghrelin concentrations or those that
accompany food restriction and/or fasting conditions have not been characterized, the capacity of
CSF acylated ghrelin to initiate GHSR dependent processes should not be completely discounted.
Furthermore, circulating acylated ghrelin is rapidly converted into des-acyl ghrelin by esterases
present in the circulation and thus CSF acylated ghrelin levels may be underestimated [59]. Therefore,
enhancing the sensitivity of current ghrelin quantification assays and developing more efficient
sampling methods that maximize recovery and mitigate degradation of acylated ghrelin may make
CSF ghrelin detection possible in rodents and more accurate in other model species. Fortunately,
compounds able to reliably prevent hydrolytic degradation of acylated ghrelin into des-acyl ghrelin
in biological samples have recently been identified [59]. These ameliorations will go a long way in
determining whether endogenous CSF ghrelin levels relevantly influence GHSR dependent behaviours
such as feeding.
Regardless, it appears that CSF ghrelin is capable of accessing various GHSR rich feeding related
brain regions as ICV injection of fluorescein-ghrelin results in a fluorescence distribution pattern
that largely overlaps with past reports examining GHSR mRNA expression (Figure 3) [13,17,190,210].
The fluorescein-ghrelin signal is attenuated by ICV administration of unlabeled ghrelin in wild-type
(WT) mice and is not observable in any nuclei of GHSR KOs suggesting that fluorescein-ghrelin
specifically binds to GHSRs [190]. The highest number of fluorescently labelled cells and brightest
signal is found in the HYP; however, positively labelled neurons are also found in many
extrahypothalamic sites (e.g., HIP, dorsal raphe nucleus, VTA, laterodorsal tegmental nucleus) [190].
Interestingly, fluorescein-immunoreactive signal is ubiquitous in ependymal like cells that border the
ventricular system (i.e., lateral, third and fourth ventricles, aqueduct of Sylvius, and the central canal)
in both WT and GHSR null mice [190]. Moreover, bright signals are detected in the cell bodies and
far reaching ME cellular projections of tanycytes that line the bottom of the third ventricle in both
genotypes [190]. These experiments highlight plausible GHSR independent processes by which CSF
ghrelin crosses the CSF brain barrier to access brain regions that house GHSRs [190]. Consistent with
this, others have reported tanycyte dependent plastic changes in the permeability of the blood CSF
interface in response to metabolic factors [169,171]. Although the GHSR independent mechanism by
which ependymal cells internalize and pass CSF ghrelin to brain parenchyma is currently unclear,
these studies suggest that CSF ghrelin can reach widespread GHSR positive BBB privileged brain
regions [190]. Advances in the collection and detection of acylated ghrelin within the CSF will clarify
whether CSF ghrelin concentrations similarly fluctuate with feeding status and are adequate to bind
and activate GHSRs. Positive results in this regard, would suggest that ghrelin uses the CSF and
ventricular system to reach its widespread CNS targets. It is important to note that according to our
knowledge no one has investigated whether GOAT is expressed in CSF. Therefore the possibility that
des acyl ghrelin is acylated in the CSF and then distributed to the aforementioned BBB protected GHSR
rich brain regions cannot be dismissed.
4.3. Central Ghrelin Synthesis
A hotly debated question amongst ghrelin researchers is whether or not ghrelin is synthesized
within the brain. Although, the contention is mainly fueled by conflicting evidence surrounding the
subject, the significance of central ghrelin synthesis in and of itself makes it an important and intriguing
topic. This is especially true since, as discussed previously, ghrelin has been predominantly viewed to
be produced exclusively in the periphery and with the exception of the ME and to a lesser extent the AP
does not appear to appreciatively cross or avoid (i.e., enter the brain via circumventricular organs) the
BBB to access central GHSRs [18,19,122]. Therefore, central ghrelin synthesis and secretion, if proven to
occur, would go a long way in reconciling why GHSRs are found in numerous BBB privileged feeding
related regions that are seemingly inaccessible to peripheral ghrelin.
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4.3.1. Support for the Central Synthesis of Ghrelin
There is a substantial amount of evidence suggesting that ghrelin is synthesized within the
brain (Table 1). To begin, many independent groups have detected ghrelin mRNA within the
brain (most commonly within the HYP) [20,22,24,56,214–219]. Second, the hypothalamic expression
of ghrelin and GOAT mRNA fluctuate with feeding status (i.e., upregulated following a 48 h
fast in rats) [56]. Although hypothalamic ghrelin mRNA is not upregulated in food restricted
animals, the transcript for GOAT is suggesting that elevations in ghrelin signaling may be due to
enhanced activation of ghrelin rather than upregulation of the peptide itself [56]. Further alluding
to the importance of central ghrelin synthesis and/or activation, chronic central GOAT knockdown
(via ICV infused amorpholino antisense oligonucleotides) significantly decreases weight gain of
rats fed a high fat diet [56]. Third, ghrelin protein has also been detected within the brain by
many independent groups [20,22,24,216,220–225]. Not surprisingly, these ghrelin producing cells
most commonly are described within hypothalamic nuclei but some extra-hypothalamic ghrelin
containing processes have been reported [20,22,24,215,219,223,224]. Studies demonstrating positive
central ghrelin immunoreactivity have been conducted in rats [20,22,24,60,215,219–221,223], mice [22],
and humans [224] and have used antibodies targeting both des-acylated [22,220,221,223,224] and
acylated ghrelin forms [24,215,219]. Oddly, although most of these studies report expression within
the ventral portion of the HYP, the precise cellular (i.e., specific neuron types) and sub-cellular
(i.e., soma versus axons/terminals) location of ghrelin differs greatly [20,22,24,60,215,219,223,224].
Since a majority of these antibodies were validated (i.e., ghrelin KO animals, pre-incubation of anti-sera
in an excess of ghrelin, etc.), the discrepancy in the distribution of ghrelin immunoreactivity appears to
reflect differences in species of study and specific ghrelin epitope targeted rather than poor specificity.
Nonetheless, many still harness skepticism concerning the specificity of currently available antibodies
as well as the validity of associated evidence supporting central ghrelin synthesis [23,25,218]. Even so,
the fact that many independent groups have utilized unique antibodies targeting different ghrelin
epitopes and all report ghrelin-immunoreactivity specifically within the HYP strongly supports the
notion that ghrelin is synthesized centrally. Moreover, Kageyama and colleagues [225] provided
support for ghrelin’s central synthesis without relying on anti-ghrelin antibodies by creating transgenic
mice that express enhanced green fluorescent protein (EGFP) in cells that produce ghrelin (i.e., inserted
the gene for EGFP in the regulatory region of the ghrelin gene). As expected, these mice express both
EGFP and ghrelin mRNA in the stomach and likewise show immunoreactivity for ghrelin and GFP
proteins within this region [225]. Importantly, ghrelin and EGFP transcripts and corresponding proteins
are detectable within the HYP of these mice, supporting the fact that ghrelin producing cells exist within
this region [225]. Lastly, radioimmunoassays of push-pull perfusion perfusates also support ghrelin’s
central production and release [226]. Ghrelin levels in the ARC were shown to rise almost 2 fold relative
to baseline following intra-ARC infusion of potassium ions (i.e., encourages depolarization) [226].
This effect was found to be extremely specific as animals with off-target probes did not demonstrate
enhanced ghrelin levels [226]. Although one cannot completely exclude the putative contribution
of peripheral ghrelin, the steep enhancement of ghrelin evoked by the potassium ions strongly
suggests local terminal vesicle release within the ARC. Collectively, the aforementioned data gathered
using a multitude of different techniques (i.e., in situ hybridization, real-time polymerase chain
reaction (RT PCR), immunohistochemistry, transgenics, push-pull perfusion, radioimmunoassays)
make a strong case for the central synthesis and release of ghrelin, at least within the medio-basal
hypothalamic region.
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4.3.2. Evidence Opposing the Central Synthesis of Ghrelin
In a similar fashion, a number of studies have provided data that refutes the notion of ghrelin’s
central synthesis (Table 1) [23,25,218]. For example, transgenic ghrelin deficient mice (ghrl−/−),
which were engineered to express a lacZ reporter gene in the place of the functional ghrelin gene,
demonstrate evident β-galactosidase staining within the stomach and intestine but no positive
staining within the HYP [218]. Furthermore, WT and ghrelin deficient mice show negligible and
indistinguishable hypothalamic ghrelin immunoreactivity despite having very different stomach
ghrelin immunoreactivity profiles (i.e., strong signal in WTs and absence of signal in ghrl−/−s) [218].
Although Wortley and colleagues were able to detect low levels of ghrelin mRNA within WT animals,
their aforementioned inability to detect acylated ghrelin or to observe β-galactosidase staining within
the HYP contradict previous claims that ghrelin is found and/or is synthesized centrally. Consistent
with this, studies run with two separate transgenic ghrelin reporter mice, in which humanized
Renilla reniformis GFP expression was driven by different lengths of the ghrelin promotor, failed to
detect GFP fluorescence in the brain but demonstrated clear GFP expression in the stomach [25]. It is
important to note that within these two transgenic ghrelin reporter mice lines no signal was observed in
other tissues known to express ghrelin to a lesser extent (i.e., pancreas, intestine, kidney) [25,28,227,228].
For instance, although in situ-produced ghrelin has been established as an important endocrine
signal for the development of the pancreas and the regulation of insulin release [229,230], ghrelin
reporter systems fail to detect a signal within this organ [25]. Therefore, although these reporter
lines appear to be useful for detecting tissues that produce high levels of ghrelin, their utility in
detecting regions that synthesize small amounts of ghrelin, as suspected within the HYP, may be
limited. Nonetheless, since ghrelin expression may vary during development, examination of these
transgenic lines during times when ghrelin is supposedly expressed most strongly may clarify whether
ghrelin reporter lines support the extragastric production of ghrelin [231]. Additionally, Sakata and
colleagues [25] failed to detect ghrelin immunoreactivity or ghrelin mRNA (via in situ hybridization)
within the brain of WT or transgenic reporter mice. Their inability to detect ghrelin mRNA or protein
within the brain argues against the central synthesis of ghrelin; however, it may also be that the
quantity of ghrelin produced within the HYP does not surpass inherent detection thresholds. Lastly,
due to concerns over the specificity and type of ghrelin (e.g., des-acyl ghrelin, preproghrelin) targeted
by antibodies in immunohistochemical studies supporting central ghrelin synthesis, in addition to
evidence of the contrary [25,218], Furness and colleagues [23] conducted a comprehensive analysis
of ghrelin protein expression in the rodent brain. They report strong signals from the stomach but
no specific immunoreactivity for either ghrelin or des-acyl ghrelin in the CNS (e.g., HYP, medulla
oblongata, and spinal cord) using four different antibodies (three targeting acylated ghrelin and one
targeting des-acyl ghrelin) [23]. The authors argue that the aforementioned histochemical studies
that demonstrate ghrelin immunoreactivity in the HYP are likely detecting ghrelin precursors or
compounds with sufficient similarities to the ghrelin peptide [23]. Collectively, the data presented
above represents the most persuasive evidence contesting the central synthesis of ghrelin.
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Table 1. Supporting and refuting evidence regarding the central synthesis of ghrelin.
Technique(s) Findings Summary Species Reference(s)
Supporting
Evidence
RT PCR Ghrelin transcript detected in the brain Rat [20]
RT PCR Ghrelin transcript detected in the arcuatenucleus (ARC) Rat [24]
RT PCR
Ghrelin transcript detected in the
hypothalamus (HYP) of wild-type (WT) but
not ghrelin knockouts (KOs)
Mouse [22]
RT PCR Ghrelin mRNA detected in HYP Rat [215]
RT PCR Ghrelin mRNA detected in cerebral cortexand HYP Rat [214]
RT PCR Hypothalamic expression of ghrelinsignificantly lower in clock mutants Mouse [217]
RT PCR
Hypothalamic expression of ghrelin and
ghrelin O-acyltransferase (GOAT) mRNA




Detected ghrelin and enhanced green
fluorescent protein (EGFP) transcripts in the
HYP of transgenic mice that were engineered
to express EGFP in cells that produce ghrelin
(i.e., inserted the gene for EGFP in the
regulatory region of the ghrelin gene)
Mouse [225]
Immunohistochemistry Ghrelin-immunoreactive neurons detected inthe ARC Rat [20,24,220,221,223]
Immunohistochemistry
Numerous ghrelin immunoreactive cell bodies
and axons found within the HYP;small number
of ghrelin immunoreactive processes found
within extrahypothalamic brain regions
(e.g., BNST, NA, cortex)
Mouse [22]
Immunohistochemistry Detected ghrelin immunoreactivity in the HYP Human [224]
Immunohistochemistry Ghrelin immunoreactive neurons weredetected in the HYP and cerebral cortex Rat [214]
Immunohistochemistry
HYP ghrelin was detected in sham operated





EGFP fluorescence detected in ARC of
transgenic ghrelin reporter mice (inserted the








Detected ghrelin radioimmunoreactivity in






Detected ghrelin radioimmunoreactivity in
the HYP Rat [215]
Behavioural tests
Chronic central GOAT knockdown
(via ICV infused amorpholino antisense
oligonucleotides) significantly decreased
weight gain of rats fed a high fat diet
Rat [56]
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Table 1. Cont.





Failed to detect ghrelin immunoreactivity or
ghrelin mRNA (via in situ hybridization)




Strong ghrelin immunoreactive signals from
the stomach but no specific immunoreactivity
for either ghrelin or des-acyl ghrelin in the
central nervous system (e.g., HYP, medulla
oblongata, and spinal cord) using four separate





Evident β-galactosidase staining within the
stomach and intestine but no positive staining
within the HYP of transgenic ghrelin deficient
mice (ghrl−/−) engineered to express a lacZ
reporter gene in the place of the functional
ghrelin gene WT and ghrelin deficient mice
show negligible and indistinguishable
hypothalamic ghrelin immunoreactivity





Failed to detect GFP fluorescence in the brain
but demonstrated clear GFP expression in the
stomach using two separate transgenic ghrelin
reporter mice (i.e., ghrelin-hrGFP BAC
transgenic mice), in which humanized
Renilla reniformis GFP expression was driven by
different lengths of the ghrelin promotor
Mouse [25]
4.3.3. Future Avenues to Ease the Central Synthesis of Ghrelin Debate
Although strong evidence exists for the central synthesis of ghrelin, equally convincing
experiments have been conducted and lend support to the opposite conclusion. It is evident that more
work is needed to clarify whether or not ghrelin is centrally synthesized in the brain. The ability to
detect ghrelin or ghrelin reporter immunoreactivity within the brain is one of the biggest points of
contention between those that believe that ghrelin is synthesized centrally and those that oppose it.
All available anti-ghrelin antibodies (including those that have detected central ghrelin and those
that have not) need to be characterized (e.g., via immunohistochemical studies) in both ghrelin deficient
and WT rodents. More specifically, this characterization should involve an in depth analysis of all
extra-gastric tissues reported to have the capacity to synthesize ghrelin and efforts should be made to
include amplification steps to maximize the detection of ghrelin in organs that may weakly produce
it (e.g., pancreas, intestine, kidney, brain). These experiments will not only be useful in identifying
which antibodies are specific but will also highlight published works that may have used non-specific
and/or poor quality antibodies. Correspondingly, this will facilitate identification of data that should
be interpreted with caution and will highlight the best antibodies to use for the future detection of
ghrelin. Measuring ghrelin levels (e.g., microdialysis) directly within the HYP with verified antibodies
would provide extremely important information pertaining to the validity of the central synthesis of
ghrelin. Unfortunately, quantifying ghrelin levels via microdialysis is not a common practice, primarily
due to low recovery (i.e., approximately 30% of actual levels) [232]. However, as ghrelin and GOAT
transcript levels within the HYP are increased following food restriction, measuring ghrelin levels
in hypothalamic regions during a time of energy insufficiency, may heighten the concentration of
ghrelin to a detectable level [56]. Likewise, early addition of alkyl fluorophosphonate compounds,
which slow the degradation of acylated ghrelin (through the inhibition of enzymes that cleave the ester
bond attaching the octonyl moiety to the rest of the ghrelin peptide), to sample perfusates should also
ameliorate detection thresholds [59]. Alternatively, high-performance liquid chromatography-mass
spectroscopy techniques could be exploited to assess central acylated ghrelin levels. It is important
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to note, that these experiments would have to be conducted in nuclei thought to be inaccessible to
peripheral ghrelin to confirm ghrelin’s central synthesis.
Lastly, current ghrelin reporter transgenic lines largely fail to express reporter genes in
extra-gastral tissues known to be able to produce and secrete ghrelin and/or demonstrate weak
signals relative to background [25,218,225]. Accordingly, generating transgenic ghrelin reporter mice
that more accurately express reporter genes in tissues and cell-types that naturally produce ghrelin
(by transfecting bacterial artificial chromosomes that contain larger fragments up and down stream of
the ghrelin gene) is of prime importance. If accomplished, these transgenic ghrelin reporter lines will
not only be a valuable asset in determining if ghrelin is centrally synthesized but will facilitate the
study of ghrelin cell physiology in general.
5. GHSR Activity Independent of Ghrelin
Although peripheral ghrelin clearly modulates feeding behaviours via various means
(e.g., vagal afferents, CVO entry and activation of central GHSRs) and centrally synthesised ghrelin
may also contribute, it has become apparent that GHSRs may also convey feeding related messages
independent of ghrelin [6,9,10,22,123,152,154,225,233]. Accordingly, the GHSR demonstrates very high
constitutive activity (i.e., initiates downstream signaling events in the absence of suitable ligands)
and interacts with a plethora of other GPCR in addition to itself [212,233–237]. Consistent with this,
when challenged (e.g., feeding regimes, stressed) ghrelin KO animals have different feeding behaviours
and phenotypes relative to animals that lack a functional ghrelin receptor (i.e., GHSR KO or GHSR
null rodents) [1,38,238–241]. Ghrelin independent activation of GHSRs may help rectify the apparent
discontinuity between the ubiquitous expression of GHSRs within BBB protected feeding related brain
regions and the limited accessibility of ghrelin to these regions. The following sections will describe the
putative roles that GHSR constitutive activity and dimerization play in modulating feeding behaviours.
5.1. GHSR Constitutive Activity
A vast majority of GPCRs are constitutively actively to some extent; however, the degree
of constitutive activity displayed by the GHSR is uniquely high [212]. It has been reported that
the GHSR, on its own, can signal at about half the capacity as that elicited following ghrelin
binding [212,242]. This estimation has been substantiated using a number of different assays and
measures (e.g., inositol phosphate turnover and cyclic adenosine monophosphate (cAMP) response
element-induced transcriptional activity) [212,242]. Although it has been argued that the reported
constitutive activity of the GHSR is overinflated due to assay dependent parameters (e.g., unnaturally
high levels of expression in heterologous systems or intrinsic modulators) [233,235,243], studies that
limit many of these confounds confirm the high constitutive activity of GHSRs and report that it is an
intrinsic property of the receptor [244].
Modulation of this high constitutive activity has corresponding ramifications on GHSR dependant
biological processes such as feeding and energy balance [242,245–247]. A study examining a genetic
mutation in the GHSR gene, shared amongst individuals with familial short stature, was the first to
examine the in vivo consequences of altered GHSR constitutive activity [246]; however, the importance
of ligand independent GHSR basal activity in regulating appetite had been previously suggested [242].
The in vivo use of [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P, a weak antagonist but potent inverse
agonist (counteracts downstream signaling cascades induced by GHSR activation) of the GHSR,
clarified the necessity of basal GHSR activity in the regulation of feeding and energy balance [212,247].
Accordingly, central blockage of constitutive activity, via chronic ICV administration of [D-Arg1,
D-Phe5, D-Trp7,9, Leu11]-substance P, is sufficient to decrease both food intake and body weight as well
as the hypothalamic expression of NPY and uncoupling protein 2 (UCP-2) compared to controls [247].
The alteration in NPY and UCP-2 expression is suspected to be mediated by GHSR dependent cAMP
response element-binding protein (CREB) phosphorylation, as CREB phosphorylation is increased by
ghrelin and decreased by [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P in hypothalamic cell lines [247].
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Likewise, ICV administration of another potent GHSR inverse agonist (i.e., K-(d-1-Nal)-FwLL-NH2),
known to counteract GHSR constitutive activity, severely decreases short term food intake (almost
5-fold) relative to control animals [245]. Further corroborating a role for GHSR constitutive activity in
regulating feeding, presynaptic constitutive GHSR activity impairs calcium currents within rodent
hypothalamic ARC neurons and reduces GABA release from these explants [248]. Lastly, alluding to
a means for the regulation of constitutive activity, GHSRs are upregulated in the HYP during times
of energy insufficiency (i.e., during fast or chronic food restriction) when food procuring behaviours
are needed [56,248–251]. Collectively these data strongly suggest that high GHSR constitutive activity
is important for regulating energy balance (i.e., feeding and metabolism) and highlight the HYP as
at least one location whereby this activity engages signaling events that promote orexigenic neural
circuits [247]. Furthermore, it highlights the efficacy that inverse agonists have with respect to curbing
food consumption and thus their therapeutic potential in combating excessive feeding [242,245].
5.2. GHSR Promiscuity
Heterodimerization between GPCRs is an increasingly apparent phenomenon that is attracting
a lot of attention given the functional and physiological implications associated with it. It not only
provides another means by which central systems can influence one another but also alters the way in
which we interpret data. Accordingly, heterodimerization between GPCRs can alter the strength and/or
nature of downstream signalling cascades transduced by corresponding monomeric GPCRs [251,252].
These changes are most frequently a consequence of altered ligand binding, G-protein selection,
or modified receptor trafficking to or from the cell membrane (i.e., receptor internalization) [253,254].
Importantly, the realization of the existence and prevalence of heterodimer formation may partially
explain the distribution pattern and function of receptors thought to be inaccessible to their respective
ligands, particularly the GHSR [233,255]. Accordingly, GHSR-1as (growth hormone secretagogue
receptors type 1a), which up until this point have been referred to simply as GHSRs, have the capacity
to form heterodimers with many GPCRs: most notably GHSR-1bs, melanocortin 3 receptors (MC3-Rs),
serotonin 2C receptors (5-HT2C), and dopamine receptors 1 (DRD1) and 2 (DRD2) [235–238,256–261].
These heterodimers have been characterized in vitro and are just starting to be examined in ex vivo
and in vivo studies [235–238,257,259,261]. Evidence supporting the formation of these heterodimers
and their potential role in regulating feeding will be discussed subsequently (Table 2). It is important to
note that to date the physiological in vivo evidence that may be used to support theories of heterodimer
formation in vivo may simply be indicative of an interaction between two systems. More advance
techniques and rigorous testing are needed to confirm the location and prevalence of heterodimers
in vivo and the extent to which they may influence signaling cascades and ultimately behaviour.
As stated throughout this paper, activation of central GHSRs unequivocally enhances both the
motivation and consumption of food [6,10,67,70,119,122,209]. The α G-protein subunit (i.e., αq, αs,
orαi/o) that GHSRs associate with and the corresponding signaling cascades that are initiated following
ghrelin binding are diverse and are influenced by a multitude of factors (e.g., tissue, cell type,
heterodimer partner) [4,262–264]. Most commonly, GHSRs couple with Gαq and upon activation
elicit increases in intracellular calcium via phospholipase C/inositol triphosphate (PLC/IP3) signalling
cascades [4,13,261,263,264]. Particularly, within the HYP, this rise in intracellular calcium is important
for the mobilization of calcium/calmodulin-dependent protein kinase II (CaMKII) and subsequent
activation of AMPK signalling cascades that promote orexigenic responses [68,265–268]. GHSR Gαs
dependent stimulation of AMPK via cyclic adenosine monophosphate/protein kinase A (cAMP/PKA)
signaling cascades have also been reported [222,268]. Ghrelin is likewise capable of stimulating GHSR
dependent signalling pathways that are sensitive to pertussis toxin indicating that the GHSR can also
associated with Gαi/o [269,270]. It is clear that the GHSR, like most GPCRs, is extremely versatile in that
it can transduce signals through various signalling cascades depending on its microenvironment [263].
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Table 2. Summary of GHSR-1a heterodimers and their putative implication in regulating feeding behaviours.










Low ratio of GHSR-1b relative to GHSR-1a
↑cell surface expression of the heterodimer
and↑Gαi/o dependent signaling cascades
following ghrelin administration [258]
High ratio of GHSR-1b relative to
GHSR-1a↓cell surface expression of the
heterodimer and↓Gαi/o dependent
signaling cascades following ghrelin
administration [258]
Increasing the expression of
GHSR-1b in striatal (i.e., naturally
high GHSR-1b to GHSR-1a
expression ratio) cultures↓ghrelin
signalling efficiency [258]
Increasing the expression of





If GHSR-1b subunit is much higher
than GHSR-1a then the
GHSR-1a/GHSR-1b heterodimer
can still bind agonists but forfeits
the capacity to stimulate associated
signaling proteins [257]
Unknown but speculated↑in
feeding when ratio of GHSR-1a
to GHSR-1b is high but↓in
feeding when ratio of GHSR-1a




and give off a reliable positive
bioluminescence resonance energy transfer
signal only in the presence of agonists
(i.e., dopamine and ghrelin) [234]
Enhances Ca2+ and cAMP accumulation in
HEK cells in response to ghrelin and
dopamine above those observed when
GHSR or DR1D are expressed alone [234]
DRD1 agonists significantly enhance
the formation of GHSR/DRD1
heterodimers within hippocampal
neurons [157]
DRD1 and GHSR agonists enhance
Ca2+ in WT neurons that express the
heterodimer but are unable to elicit
this effect in GHSR antagonist treated




Pre-treatment with a D1-like
antagonist into the NA, completely









DRD2 agonists↑intracellular calcium levels
in HEK 293 cells which co-express both
GHSR-1as and DRD2s but not in cells
transfected with either receptor
independently [235]
HEK 293 cells that are pre-treated with
either DRD2 or GHSR antagonists do not
enhance intracellular calcium levels in
response to DRD2 or GHSR agonists [235]
FRET detection of GHSR-1a/DRD2
heterodimers in hypothalamic




DRD2 agonists known to suppress
appetite, reliably↓food intake in
WT but not GHSR KO mice [235]
Pre-treatment of WT mice with
GHSR antagonists, prevent
decreases in feeding following
cabergoline injections [235]
Pre-treatment with a D2-like
antagonist into the NA, completely
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When GHSR-1as and 5-HT2C receptors are
co-transfected into HEK 293 cells they
co-localize [236]
GHSR-1a agonists significantly↑the
co-internalization of these receptors in
HEK 293 cells [236]
Co-transfection of GHSR-1a and 5-HT2C in
HEK 293 cells reduces GHSR agonist
induced GHSR signaling activity
(65% in Ca2+ mobilization) [236]
Unknown HIP, HYP, VTA, Cortex[12–14,271–273]
Peripheral administration of
5-HT2C receptor agonists block
the↑in plasma ghrelin seen
following a 24 h fast and increases
expression of anorexigenic peptides
within the HYP [273]
Intra-PVN microinjections of
5-HT2C agonists significantly
attenuates the orexigenic effect of
intra-PVN ghrelin [274,275]
GHSR activation by ghrelin blocks







Co-transfection of GHSRs and MC3-Rs in
COS-7 cells potentiates α-MSH induced
cAMP accumulation [260]
Co-transfection of these receptors in HEK




The orexigenic effects of peripheral
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5.3. GHSR Dimers
Interestingly, although homodimerization between GHSR-1as does not appear to significantly
alter ligand binding, G-protein selection, or constitutive activity relative to GHSR-1a monomers,
heterodimerization between GHSR-1a and its truncated splice variant, GHSR-1b, has been shown
to greatly impact these processes [235,257,280]. The GHSR-1b, which lacks transmembrane domains
6 and 7, does not possess signaling capabilities as a monomeric unit; although, evidence suggests that it
may be an integral unit of other functional GPCR oligomers (i.e., GHSR-1a/GHSR-1b/DRD1) [258,261].
Accordingly, heterodimer studies in lipid discs have demonstrated that the GHSR-1a/GHSR-1b
heterodimer retains the ability to bind GHSR-1a agonists but loses the capacity to stimulate associated
signaling proteins (i.e., Gαq protein or arrestins), ultimately stranding the heterodimer in a non-active
state [257]. Consequentially, the heterodimer does not possess the typical high constitutive activity
intrinsic to GHSR-1as [257]. This data supports earlier work done in HEK 293 cells demonstrating
that co-expression of GHSR-1a and GHSR-1b leads to heterodimer formation, normal ghrelin binding
but reduced GHSR-1a constitutive activity and cell surface expression [280]. More recent analysis of
this heterodimer in HEK 293 cells shows that the cell surface expression of the heterodimer is actually
dependent on the ratio of GHSR-1b versus GHSR-1a (i.e., ratio can be manipulated by co-transfecting
cells with disparate quantities of receptor cDNA) [258]. Accordingly, a low ratio of GHSR-1b relative to
GHSR-1a promotes cell surface expression of the heterodimer and enhances Gαi/o dependent signaling
cascades in response to ghrelin administration [258]. Conversely, a high ratio of GHSR-1b relative
to GHSR-1a decreases cell surface expression of the heterodimer and dampens GHSR-1a signalling
following ghrelin administration [258]. Interestingly, these findings were substantiated in striatal and
hippocampal primary cultures which naturally express high and low GHSR-1b and GHSR-1a ratios
respectively [258]. As expected, artificially raising the expression of GHSR-1b in striatal (i.e., naturally
high GHSR-1b to GHSR-1a expression ratio) and hippocampal (very low inherent GHSR-1b/GHSR-1a
expression ratio) cultures decreased and increased the signaling efficiency of ghrelin respectively [258].
These studies suggest a means by which neurons that express these receptors may self-regulate
GHSR-1a signalling. Likewise, it was discovered that although this heterodimer preferentially signals
via Gαi/o dependent signaling cascades in HEK 293 cells, in both primary cultures it favourably
couples to Gαs to drive cAMP production [258]. The physiological roles of this heterodimer and
magnitude of its importance in modulating behaviours, especially feeding, have yet to be thoroughly
explored; however, given the signaling pathways that the heterodimer initiates in neurons (primarily
Gαs), the co-expression of GHSR-1a and GHSR-1b in feeding related brain regions (i.e., hippocampus
and striatum), and that GHSR-1b has recently been found to play an important role in a functional
GPCR oligomer (i.e., GHSR-1a/GHSR-1b/DRD1) (will be discussed subsequently), it is evident that
its influence requires further investigation (Table 2).
5.4. GHSR and Dopamine Receptor Heterodimers
The investigation of a putative heterodimer pairing between GHSRs, DRD1s, and DRD2s was
inspired by commonalities in the localization of their mRNA, similarities in signaling cascades, and the
realization that these systems modulate some of the same physiological processes [13,236,256,281–286].
In general, stimulation of DRD1s induces cAMP/PKA signalling cascades via Gαs dependent processes;
whereas, DRD2 activation conversely activates Gαi coupled proteins to antagonize cAMP production
and PKA activity [284,287–290].
Neurons within the HIP, VTA, and substantia nigra, co-express GHSR and DRD1 receptors [234].
Furthermore, these receptors co-localize in the same sub-cellular location, immuno-precipitate
together, and give off a reliable positive bioluminescence resonance energy transfer (BRET) signal
solely in the presence of ligands (i.e., dopamine and ghrelin) [234]. In vitro studies conducted
in HEK 293 cells co-transfected with both DRD1s and GHSRs show that dopamine and ghrelin
synergistically enhance cAMP accumulation above the modest stimulation of dopamine and the
negligible induction of ghrelin alone [234]. It appears that the potentiation of cAMP accumulation
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(following co-administration of ghrelin and dopamine) involves the exchange of GHSR associated
Gαq to Gαi/o,, the consequential release of accompanying βγ subunits and the final potentiation
of dopamine Gαs mediated cAMP accumulation via the engagement of adenylyl cyclase [234].
Interestingly, others suggest that GHSR-1b is also important for the association of GHSR-1a with
DRD1 at least within striatal primary cultures [258]. Consistent with this, treatment of striatal primary
cultures with DRD1 antagonists prevents the traditional increase in cAMP levels seen following ghrelin
administration in GHSR-1a/GHSR-1b dimer experiments [258]. Collectively, these data provide
evidence of a collaborative interaction between GHSRs (i.e., both GHSR-1a and GHSR-1b) and the
DRD1 (Table 2).
Recently, the functional and physiological role of the GHSR/DRD1 heterodimer within the
HIP was explored [256]. Interestingly, DRD1 agonists significantly enhance the formation of
GHSR/DRD1 heterodimers within hippocampal neurons [256]. DRD1 and GHSR agonists enhance
Ca2+ in WT neurons that express the heterodimer but are unable to elicit this effect in GHSR
antagonist treated and GHSR KO hippocampal neurons suggesting that the heterodimer is required
for Ca2+ mobilization [256]. The rise in intracellular calcium is elicited by PLC/IP3 signalling
cascades and is dependent on the association of DRD1 with Gαq rather than its usual Gαs
partner [256]. Most intriguingly, signaling through the heterodimer was deemed essential for enhancing
N-methyl-D-aspartate (NMDA) currents integral to the induction of long term potentiation and
stimulation of synaptic plasticity within the HIP, processes important for hippocampal behaviour and
memory [256]. Accordingly, GHSR inactivation, via genetic and pharmacological means, completely
attenuates DRD1 regulated hippocampal behaviour and memory (i.e., dopamine induced interference
of pre-pulse inhibition and consolidation of contextual fear conditioning) supporting an important
physiological role for the GHSR/DRD1 heterodimer [256].
The implications of GHSR/DRD1 heterodimers in relation to feeding has yet to be directly
explored; however, there are some findings, in addition to the aforementioned evidence of its
capacity to influence behaviour within the HIP that suggest it may likewise play a role in regulating
feeding [256]. First, GHSR and DRD1 transcripts are both highly expressed in feeding related regions
such as the HYP and mesolimbic dopamine system [13,258,281,290]. Second, modulation of GHSR
activity influences behaviours regulated by the dopamine system [1,101,113,118,119,282,291]. Third,
like alteration of GHSRs, selective modulation of DRD1s influences food intake (although in the
opposite direction) [292–295]. Lastly, the ability of ghrelin to modulate food reward behaviours relies
on functional DRD1s [116]. Together these data support a putative role for GHSR/DRD1 heterodimers
in the regulation of feeding behaviours and highlight the merit of its investigation.
Similarly, several pieces of evidence suggest that GHSRs can also form heterodimers with DRD2s.
Accordingly, although DRD2 and GHSR mRNA and protein coexist within neurons of the HIP,
striatum, and HYP, these receptors co-localize most strongly within the HYP [235]. Consistent with this,
fluorescence resonance energy transfer microscopy experiments report GHSR-1a/DRD2 heterodimers
in hypothalamic preparations of WT but not GHSR KO animals [235]. Moreover, molecular studies
also support the formation of this heterodimer as DRD2 agonists increase intracellular calcium levels
in HEK 293 cells which co-express both GHSR-1as and DRD2s but fail to in cells transfected with either
receptor independently or in cells pre-treated with either DRD2 (i.e., raclopride) or GHSR antagonists
(i.e., JMV 2959) [235]. In these cells, allosteric interactions between GHSRs and DRD2s have been
deemed essential for the mobilization of intracellular Ca2+ in response to bath applications of dopamine.
This effect relies on the heterodimer coupling to Gαi, release of Gβγ subunits and subsequent induction
of PLC/IP3 signalling cascades (mediated by the βγ subunits) [235]. It is also independent of GHSR
constitutive activity as attenuating GHSR constitutive activity (via point mutations of GHSR or
introduction of Gαq siRNA) does not significantly blunt the calcium response [235]. Consistent with
the existence of GHSR-1a/DRD2 heterodimers, pre-treatment of cells with either GHSR-1a or DRD2
agonists reduces Ca2+ release induced by subsequent dopamine or ghrelin treatment respectively
(i.e., cross desensitization) [235].
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The fact that activation or suppression of DRD2, like modulation of GHSRs, influences feeding
behaviours in addition to evidence of their structural and functional interaction in vitro led to
investigations concerning the physiological relevance of this heterodimer in vivo [235,295,296].
Accordingly, WT mice peripherally injected with cabergoline, a DRD2 agonist known to suppress
appetite, reliably decrease their food intake relative to controls; whereas, cabergoline has absolutely no
effect on the food consumption of GHSR KO mice [235]. Furthermore, pre-treatment of WT animals
with JMV-2959, a GHSR antagonist, prevents the anticipated decrease in feeding following cabergoline
injections [235]. Interestingly, this effect is ghrelin independent as both ghrelin WT and KO animals
decrease their food intake in response to cabergoline [235]. Therefore, the appetite suppressant ability
of DRD2 agonists rely on GHSR-1as but not on the presence of ghrelin.
Collectively, these experiments not only support the existence of GHSR/DRD2 heterodimers but
provide insight into the heterodimer’s downstream signalling pathways (i.e., binding of GHSRs
to DRD2s allosterically alters DRD2 canonical signaling transduction leading to increased Ca2+
mobilization) (Table 2). Unfortunately, the aforementioned studies have primarily focused on the
impact that this heterodimer has on canonical DRD2 signaling pathways and behaviours. How this
heterodimer influencing signaling through GHSRs and the behavioural consequences of modulating
normal GHSR signalling has been largely ignored. Similar studies that probe the relevance of
this heterodimer in modulating GHSR signaling and associated behaviours would be extremely
valuable. Nonetheless, these experiments highlight that GHSR/DRD2 heterodimers have the capacity
to alter ghrelin and dopamine system signaling cascades and ultimately behaviours, particularly those
responsible for the regulation of feeding. They also lend support to the notion that GHSRs situated in
brain regions considered to be inaccessible to ghrelin can still exert ligand independent control over
important behaviours like feeding.
5.5. GHSR/5-Hydroxytryptamine2C Heterodimers
The serotonin system has garnered a tremendous amount of research in recent years as
modulation of the serotonin systems profoundly influence appetite and weight. Enhancing serotonin
(i.e., 5-hydroxytryptamine (5-HT)) neurotransmission is known to suppress appetite while dampening
serotonin signalling leads to hyperphagia and weight gain [297,298]. The role of the 5-HT2C serotonin
receptor in regulating feeding behaviours has been particularly well described [299,300]. Accordingly,
5-HT and 5-HT2C receptor agonists blunt feeding responses in a 5-HT2C receptor antagonist reversible
manner [301–305]. Moreover, transgenic mice specifically lacking 5-HT2C receptors are hyperphagic
and obese, further substantiating that signalling through this receptor is important for the regulation
of appetite [305,306]. 5-HT2C receptor mRNA and protein are ubiquitously found within the brain,
including brain region known to regulate feeding [271,272]. Interestingly, its expression within feeding
related regions (e.g., HYP), like that of GHSRs, fluctuates with feeding status (i.e., fasted versus fed)
with higher 5-HT2C receptor mRNA reported in the fasted state [273]. Moreover, similar to the GHSR,
the 5-HT2C receptor, transduces its signal most commonly through a Gαq dependent pathway that
ultimately increases intracellular calcium via PLC/IP3 signalling cascades [307].
The expression and functional overlap between ghrelin and serotonin systems has provoked
research into their potential interaction [13,14,17,271,272]. Most studies have demonstrated that ghrelin
and serotonin systems work to antagonize one another but the mechanism by which they do so remains
elusive. Accordingly, peripheral administration of 5-HT2C receptor agonists blocks the increase in
plasma ghrelin seen following a 24 h fast and increase expression of anorexigenic peptides within the
HYP [273]. Conversely, in hypothalamic synaptosomes, activation of GHSRs by ghrelin blocks the
release of serotonin [276]. More importantly, intra-PVN microinjections of 5-HT2C receptor agonists
(pre-treatment) significantly attenuates the orexigenic effect of intra-PVN ghrelin [67,274,275]. Together
these data support a functional antagonistic relationship between ghrelin and serotonin systems.
Although the crosstalk between these systems is not necessarily indicative of a relationship at
the receptor level, given the promiscuous nature of the GHSR and overlapping distribution of GHSRs
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and 5-HT2C receptors, the possibility that they influence one another via heterodimerization cannot
be ignored (Table 2) [237,271,272]. Consistent with this, when HEK 293 cells are co-transfected with
GHSRs and 5-HT2C receptors these receptors co-localize [236]. Even though both GHSR and 5-HT2CT
receptors typically couple to Gαq to elicit increases in intracellular calcium, concomitant treatment
with both receptor agonists does not elicit synergistic or additive calcium influx in co-transfected
cells relative to administration of either agonist separately [236]. Interestingly, treatment with GHSR
agonists significantly increases the co-internalization of these receptors, an effect that is reversed
(i.e., increased surface expression) when cells expressing both GHSR and 5-HT2C receptors are treated
with a GHSR inverse agonist (i.e., [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P) [236]. Accordingly,
[D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P pre-treatment of co-transfected cells enhances serotonin
induced calcium influx, an effect noticeably absent in cells co-transfected with just 5-HT2C receptors
(indicative of cross sensitization) [236]. The heterodimer pairing between GHSRs and 5-HT2C receptors
in co-transfected HEK 293 cells also causes a reduction in GHSR agonist induced GHSR signaling
activity [236]. This is exemplified by the 65% reduction in calcium influx following administration
of GHSR agonists in cells co-transfected relative to those transfected with the GHSR alone [236].
Furthermore, 5-HT2C receptor antagonist pre-treatment is capable of restoring ghrelin induced calcium
influx (equivalent to levels seen in cells only transfected with GHSR) in cells co-expressing GHSR
and 5-HT2C receptors [236]. Together, these data highly suggest that GHSR and 5-HT2C receptors are
capable of forming heterodimers, a paring that severely hinders the signaling capability normally
conveyed by GHSR but does not significantly alter 5-HT2C receptor signaling. It is important that
we validate the existence of this heterodimer in ex vivo or in vivo experiments before we begin to
speculate on its physiological relevance. Nonetheless, given the prevalence of the 5-HT2C receptor in
feeding related brain regions known to house GHSR and the impact that 5-HT2C receptor antagonists
and agonists have on feeding behaviours, it remains a promising avenue of exploration.
5.6. GHSR/Melanocortin Receptor 3 Heterodimers
The role that MC3-Rs have in the regulation of feeding is slightly more ambiguous as some report
hypophagia in MC3-R KO rodents whilst others report no changes in feeding behaviour [308–310].
Moreover, MC3-Rs seem to play an important role in entrainment of anticipatory activity precluding
meals as MC3-R KOs show deficits in anticipatory behaviours relative to WT animals [310]. Although
it was originally proposed that activation of MC3-Rs suppressed feeding primarily due to the use of
nonspecific melanocortin agonists that also stimulated anorexigenic MC4-Rs; studies conducted
with more specific MC3-R agonists suggest that MC3-R activation promotes appetite [311–316].
Accordingly, administration of specific MC3-R antagonists decreases feeding in rodents [314].
Mechanistically, activation of MC3-Rs, located predominantly on POMC neurons within the ARC
(but also found on AGRP neurons), acts to dampen POMC neuron activity to promote orexigenic
pathways [312,313,315–318]. Likewise, it was recently demonstrated that activation of VTA MC3-Rs
enhances the motivational drive to obtain palatable foods and therefore may likewise contribute to the
orexigenic effects observed following MC3-R agonist administration [277].
Investigations into whether GHSR and MC3-R form heterodimers led to the realization that
GHSRs and MC3-Rs demonstrate considerable in vivo expression overlap, particularly within the
ARC [260]. Combined in situ hybridization and immunohistochemistry experiments reveal that a
vast majority of GHSR expressing cells within this region also express MC3-Rs [260]. Generally,
activation of MC3-Rs stimulates cAMP production via Gαs dependent signaling [318]. Co-transfection
of GHSRs with MC3-Rs in COS-7 cells potentiates α-MSH induced cAMP accumulation about two
fold more than those observed when the MC3-R is transfected alone [260]. Conversely, co-transfection
of these receptors in HEK 293 cells reduces basal as well as induced canonical GHSR signaling
(i.e., over 50% reduction) [236,260]. The potentiation of α-MSH induced cAMP accumulation conveyed
by the GHSR/MC3-R is dependent on GHSR constitutive activity as transfection of mutants that
do not demonstrate basal activity or treatment with GHSR inverse agonists completely abolish
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this effect [260]. Interestingly, the heterodimer is found preferentially in the cytosol of HEK-cells
co-transfected with both receptors, an effect that is not seen when the receptors are expressed on
their own [236]. The internalization of the heterodimer does not rely on GHSR constitutive activity
and becomes more prevalent when these cells are treated with GHSR but not MC3-R agonists [236].
These molecular studies present strong evidence that GHSRs and MC3-R form heterodimers; however,
confirmation of this heterodimer in vivo and its functional significance are required.
Although behavioural studies probing the relevance of this heterodimer have not been conducted,
there are observations that these two systems interact to influence feeding behaviours (Table 2). First,
these receptors are both expressed in feeding related brain regions and co-localize on the same cells
at least within the HYP [13,14,17,277,278]. Indirect evidence suggest that they may also co-localize
in the VTA as MC3-Rs are expressed on VTA dopamine neurons and 50%–60% of VTA dopamine
neurons are known to express GHSRs [1,17,277]. Second, independent stimulation of either system is
known to enhance both homeostatic and hedonic feeding behaviours [1,10,22,101,113,277,312,314,315].
Lastly, the orexigenic capability of peripheral ghrelin in WT animals is lost in MC3-R KO animals [280].
Taken alone, the above mentioned observations do not overwhelming suggest a functional relevance
for the GHSR/MC3-R heterodimer; however, in combination with the GHSR/MC3-R in vitro data,
it appears that that the physiological relevance of this heterodimer warrants further exploration,
particularly in relation to its role in regulating feeding.
6. Conclusions
Since the discovery of the GHSR and its endogenous ligand our understanding of the ghrelin
system has evolved immensely. Although ghrelin induced growth hormone release was the first
described event following activation of GHSRs, it is now known that the ghrelin system is intimately
involved in regulating many physiological processes (e.g., feeding, mood, adiposity, memory).
Ghrelin’s influence over these physiological processes and behaviours were largely determined by
administering modulators (i.e., agonists or antagonists) of GHSR signaling in GHSR rich brain regions
of known function. Interestingly, although exogenous ghrelin clearly has the capacity to activate GHSR
within many of these BBB protected brain regions to alter behaviour; the ability of endogenous ghrelin
to do so has been strongly questioned. As delineated in this manuscript these reservations stem from
the fact: that ghrelin is predominantly activated and secreted from the stomach, that an extremely low
percentage of ghrelin circulates in its active acylated form capable of stimulating GHSRs, and that
ghrelin has poor BBB penetrance and thus does not seem to be able to access many brain regions
known to house GHSRs. Although, the ghrelin system regulates various physiological processes its
ability to manipulate feeding behaviours is by far the best characterized. Nonetheless, how the ghrelin
system influences feeding processes given the apparent enigmatic spatial separation of GHSR and its
endogenous ligand has been largely ignored. The goal of this paper was to address this deficiency and
present the most likely means by which the ghrelin system modulates feeding.
Although it is often favoured to think of hormones acting in a homogenous fashion and/or within
discrete brain regions, the complexity of behaviours (particularly ones integral to survival such as
feeding) do not conform to these simplifications. In reality, it is increasingly apparent that the ghrelin
system modulates feeding behaviours in a multifaceted manor. It is clear that peripheral ghrelin
can stimulate both central and peripheral GHSRs to transduce orexigenic signals that drive feeding
behaviours. Moreover, although hotly contested, evidence of central ghrelin synthesis/activation
suggest that feeding behaviour may be locally regulated, at least within the HYPs. Lastly, although in
its infancy, the study of ghrelin independent activity of GHSR and its influence over the regulation of
feeding behaviours is emerging.
It appears that peripherally produced ghrelin predominantly exerts its orexigenic activity via two
main avenues. First, via stimulation of GHSRs located on vagal afferents (which conveniently reside in
close proximity to the main site of acylated ghrelin production) and subsequent relay of orexigenic
signal from the NTS to the HYP. Second, via activation of the well described GHSR dependent
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orexigenic circuit that originates in the ARC. Although the access of ghrelin into the ARC has long been
debated, recent studies demonstrating nutrient dependent changes in fluorescently labelled ghrelin
binding with the ARC convincingly support the ARC as an accessible brain region to peripheral
ghrelin. Although CVOs have been suspected entry sites for peripheral ghrelin, it does not seem that
peripheral ghrelin targets CVOs to gains access to GHSR rich brain within the CNS (aside from the
ME). Nonetheless, it appears that orexigenic signals can be produced in some CVO, most convincingly
in the AP, and then transmitted to other feeding related brain regions to promote feeding behaviours.
The notion of central ghrelin synthesis and/or activation has been through rigorous testing
given its revolutionary implications. Accordingly the central production of ghrelin would have many
benefits over the peripheral production of ghrelin including bypass of the BBB, decreased degradation
of acylated ghrelin, and increased spatial and temporal control. Currently, the jury is still out on central
ghrelin synthesis as it has not be indubitably demonstrated or discredited. As mentioned, validated
antibodies that creditably target acylated ghrelin and better designed ghrelin reporter transgenic lines
are desperately needed to resolve debated concerning the central synthesis of ghrelin.
Lastly, and perhaps the most important realization is the idea that GHSR ligand independent
activity may regulate the vast majority of processes that up until now have been attributed to ghrelin
dependent activation of GHSRs. The notion of GHSR ligand independent activity provides a reasonable
explanation as to why GHSRs are so widely distributed in brain regions seemingly inaccessible
to ghrelin. Furthermore, the added complexity of ghrelin independent GHSR activity may help
rationalize commonplace disparities in both in vitro and behavioural experiments. In addition to the
high constitutive activity of GHSRs, they also have the capacity to form heterodimer with at least
5 other GPCRs known to regulate feeding neurocircuits. Research into the molecular and physiological
ramifications of these heterodimers in vivo will most likely reveal previously unknown intricacies that
influence feeding behaviours.
Ultimately, it is evident that the regulation of feeding behaviours by the ghrelin system is far more
complex than originally anticipated. Not only may ghrelin act and be produced both peripherally
and centrally, but GHSRs themselves, as well as in concert with other GPCRs possess the ability to
convey significant feeding related information. Although it will take years before these complex
relationships are disentangled, the knowledge and novel therapeutic strategies uncovered along the
way will irrefutably be worth the effort.
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